{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.64","upperLimit":"1.06","value":"0.8"},{"groupId":"OG001","lowerLimit":"0.68","upperLimit":"1.47","value":"1.0"}]}],"title":"Pre-vaccination"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.76","upperLimit":"1.37","value":"1.0"},{"groupId":"OG001","lowerLimit":"1.39","upperLimit":"3.89","value":"2.3"}]}],"title":"4 weeks post-vaccination"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"description":"Anti-pneumococcal antibody was measured immediately prior to and 4 weeks after administration of a 23-valent pneumococcal polysaccharide vaccine. The pneumococcal antibody assay was a fluoroimmunoassay that used a Luminex Multiplex platform. Purified capsular polysaccharides isolated from 12 serotypes of S. pneumonia were covalently attached to microbeads and used as a capturing reagent. Phycoerythrin conjugated anti-human IgG was used for detection.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG001","title":"Methotrexate (Group B)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Immune response per-protocol population: Group A - All patients randomized to Group A who received any rituximab infusion and any vaccine and had pre-vaccination and 4-week post-vaccination blood samples. Group B - All patients randomized to Group B who received any vaccine and had pre-vaccination and 4-week post-vaccination blood samples.","reportingStatus":"POSTED","timeFrame":"Week 28 to Week 32 for Group A and Week 4 to Week 8 for Group B","title":"Serum Level of Anti-pneumococcal Antibody Measured Immediately Prior to and 4 Weeks After Administration of a 23-valent Pneumococcal Polysaccharide Vaccine","type":"SECONDARY","unitOfMeasure":"µg/mL"}